Accelerator Platforms

Start your development project with our accelerator platform services, designed to speed up phase I clinical trial readiness and derisk development approaches.

Get ready with our Developability Assessment and Preformulation Screening platform services for monoclonal antibodies (mAbs). Drawing from our extensive scientific expertise, we have designed these service platforms to help our clients determine the ideal strategy right from the start while keeping an eye on potential stage-related risks. While currently only offered for mAb programs, other applications are currently in development.

Developability Assessment

Reduce time to market and costs while mitigating risk for your mAb program with our streamlined and innovative approach. Select the most promising antibody candidates with the most favorable biophysical properties as a foundation for successful drug product development, accelerating time to market.

The Developability Assessment service package includes:

- Formulation-focused developability assessment designed to identify stable candidates suitable for high-concentration applications
- Screen antibody candidates based on biophysical properties, ensuring the selection of leads with the best chances of success in subsequent drug product development
- Supported by in silico analysis using machine learning (ML) tools and molecular dynamics simulation.
- Benchmarking to commercial antibody drug products
- Apply the full advanced method set of Coriolis for predicting stability and the influence of the formulation
- Select candidates with the greatest potential for straightforward formulation development
- Benefit from in-depth prediction of high-concentration behavior and identification of possible stability liabilities to derisk future development
- Benchmarking to commercial antibody drug products

Preformulation Screening

Go from molecule to formulation within six weeks with our preformulation screening service. Systematically screen a vast formulation space, including only excipients accepted for parenteral application, and comprehensively generate holistic drug product development data, including accelerated stability and forced degradation readouts. This approach allows for the careful selection of lead formulations for subsequent stability studies and further preclinical drug product development for your mAb program.

- Preparation of 80 formulation variants
- Conformational stability
- Colloidal stability
- Chemical stability
- Protein–protein interaction
- Basic characterization
- Standardized data analysis and visualization
- Focused design of experiments evaluation
- Result interpretation from Coriolis experts
- Heat maps for formulation selection

We’ve worked with more than 930 compounds, and that number is growing by the day.

Your Drug Product

Coriolis Pharma’s deep expertise across many biologic modalities, combined with input from world-leading external advisors, offers the knowledge and experience needed to solve even the most complex formulation and drug development challenges. We’ve worked with more than 930 compounds, including drug substances like live virus vaccines, viral vectors or cell therapies that require biosafety level 2.

Antibody or Related Product

Peptide

Therapeutic Protein

Gene & Cell Therapy

Viral Vector

Nucleic Acid

Vaccine

Nanoparticulate Delivery Systems

Your Phase

Our expert team has the knowledge and experience to guide your program from discovery to preclinical drug development, through clinical phases and to the market.

Preclinical

Early Phase

Late Phase & Commercialization

Commercial Services

Coriolis Effect

See how our expertise and comprehensive services accelerate biologics development from preclinical to the market.